Animal Models of Trichomonas vaginalis Infection with Special Emphasis on the Intravaginal Mouse Model

Hayward-McClelland, S.F.; Delgaty, Kiera L.; Garber, Gary

doi:10.1016/b978-012775390-4/50239-6

Cited by 2 publications

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results showed that immunized mice either were protected or cleared the infection faster than sham-vaccinated or naive mice did. Nonvaccinated mice cured with metronidazole were not protected from vaginal infection and showed no immune response, whereas vaccinated mice had elevated levels of anti-T. vaginalis antibodies in both serum and vaginal secretions (42).…”

Section: Vaccinesmentioning

confidence: 99%

Treatment of Infections Caused by Metronidazole-ResistantTrichomonas vaginalis

et al. 2004

View full text Add to dashboard Cite

Infections with the sexually transmitted protozoan Trichomonas vaginalis are usually treated with metronidazole, a 5-nitroimidazole drug derived from the antibiotic azomycin. Metronidazole treatment is generally efficient in eliminating T. vaginalis infection and has a low risk of serious side effects. However, studies have shown that at least 5% of clinical cases of trichomoniasis are caused by parasites resistant to the drug. The lack of approved alternative therapies for T. vaginalis treatment means that higher and sometimes toxic doses of metronidazole are the only option for patients with resistant disease. Clearly, studies of the treatment and prevention of refractory trichomoniasis are essential. This review describes the mechanisms of metronidazole resistance in T. vaginalis and provides a summary of trichomonicidal and vaccine candidate drugs

show abstract

Section: Vaccinesmentioning

confidence: 99%